Preston D A
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Clin Ther. 1993 Jan-Feb;15(1):88-96.
In vitro data on bacterial susceptibility to cefaclor were collected from clinical trials conducted in 15 European countries, South Africa, Canada, and the United States. Among the respiratory pathogens, 94% of Haemophilus influenzae, 98.6% of Streptococcus pneumoniae, 98.8% of Streptococcus pyogenes, and 98.1% of Moraxella catarrhalis were susceptible to cefaclor. Over 90% of the tested isolates of the most common urinary tract pathogen, Escherichia coli, were susceptible to cefaclor. Virtually all of the pathogens that may infect skin and soft tissues, S pyogenes and Staphylococcus aureus (methicillin-susceptible strains), were cefaclor susceptible. These data confirm that the major pathogens in bacterial infections of the upper and lower respiratory tract, of the skin and related structures, and of the urinary tract remain susceptible to cefaclor after more than 13 years of widespread clinical use.
关于头孢克洛对细菌敏感性的体外数据,收集自在15个欧洲国家、南非、加拿大和美国开展的临床试验。在呼吸道病原体中,94%的流感嗜血杆菌、98.6%的肺炎链球菌、98.8%的化脓性链球菌和98.1%的卡他莫拉菌对头孢克洛敏感。最常见的泌尿道病原体大肠埃希菌,超过90%的测试分离株对头孢克洛敏感。几乎所有可能感染皮肤和软组织的病原体,即化脓性链球菌和金黄色葡萄球菌(甲氧西林敏感菌株),对头孢克洛均敏感。这些数据证实,经过13年以上的广泛临床应用后,上、下呼吸道、皮肤及相关结构以及泌尿道细菌感染中的主要病原体对头孢克洛仍保持敏感。